Investors were very enthusiastic when cannabis stocks first started trading. It was, basically, a new industry, and the outlook for legal cannabis sales was strong. But, as is typical on Wall Street, a gold rush mentality took hold, and the market was flooded with marijuana stocks. While the cannabis sector has grown, individual company performance hasn't lived up to investors' lofty expectations.
With marijuana companies' shares generally far below their early highs, a shakeout is taking shape. Weak players are going away, and stronger players are bulking up. Acquisitions are a big part of the story, with Curaleaf (CURLF +1.69%) recently unveiling an unsolicited bid for Aurora Cannabis (ACB +0.79%). Here are the companies that could be the biggest winners.
Image source: Getty Images.
The easy answer and the hard answer
What companies win when an industry is going through a period of consolidation? In the short term, the answer is pretty simple: any company that gets a takeout offer for more than its stock is currently trading at. If the deal is accepted, shareholders get a quick gain. If it is a cash deal, the money gets deposited into your brokerage account upon closing, and that's it. If there is stock involved, you need to decide whether to lock in your gains by selling the target or to stick around and own the acquirer.
NASDAQ: ACB
Key Data Points
Curaleaf's bid for Aurora Cannabis is a good example of the latter situation. Curaleaf's proposal is $4 per share, representing a 45% premium over Aurora's 30-day average price. The offer is $0.75 per share in cash and 0.3463 of a share of Curaleaf, with a cap of $5 per share if stock prices change. Aurora has basically said, we got your offer, and we'll think about it. However, Aurora's news release had a somewhat negative tone, suggesting that it won't accept the deal as it currently stands.
Which brings up the hard answer to the cannabis consolidation story. Over the long term, the biggest winners in the marijuana sector are likely to be the consolidators. They are actively expanding their businesses and gaining market share, which will, hopefully, make them better companies over the long term. Notably, Aurora itself is in on the act, recently buying Safari Flower to strengthen its position in the medical cannabis arena.
Canopy Growth and Tilray Brands
Canopy Growth (CGC +1.43%) is another stock worth looking at if you are interested in the cannabis consolidation story. The company recapitalized its balance sheet in early 2026, leaving it in a stronger financial position. And then it bought MTL Cannabis, a medical marijuana company. Canopy Growth's recapitalization included the issuance of a large number of new shares, diluting existing shareholders. So this wasn't exactly a great deal for investors, but it did reset the financial foundation. That, in turn, positioned the company to act more easily as an industry consolidator.
NASDAQ: CGC
Key Data Points
Canopy's fiscal first quarter 2027 earnings results hint that the reset may be working. Revenues increased 13%, with positive contributions from all of its business segments. However, a more interesting story may be unfolding at Tilray Brands (TLRY +3.85%).
Tilray has decided to pivot away from its marijuana focus, highlighting that its mission is "To be a leading premium lifestyle company with a house of brands & innovative products that inspire joy, wellness and create memorable experiences." It no longer sells marijuana alone; it also sells alcohol and CBD. The focus, meanwhile, is brand-centric.
NASDAQ: TLRY
Key Data Points
It recently made a big move in the alcohol space by acquiring craft brewer BrewDog. However, that was just one of many acquisitions. Since 2019, the company has added 20 new brands to its portfolio. In this way, Tilray is starting to look more like a consumer staples business than a cannabis stock.
Understand the risks involved in consolidation
Buying consolidators and holding for the long term to benefit from acquisition-led growth is a tried-and-true investment approach. Companies like Sysco (SYY +0.93%), Rollins (ROL +0.60%), and Cintas (CTAS +0.07%) have been doing the same thing for years in their respective, highly fragmented industries. However, integrating an acquisition isn't easy, and deals often require the buyer to use leverage. Sometimes consolidators implode, particularly if they are too aggressive.
In other words, only the most aggressive of investors should try to jump on the cannabis consolidation story. But, if you do, you should take a close look at Canopy and Tilray. Canopy because its balance sheet reset could help set it up for long-term success. Tilray, because it is taking a differentiated approach that seems like it could be fundamentally stronger than focusing only on marijuana.
